Hyperphosphatemia is a very common adverse effect of FGFR inhibitors because the FGFR1 signaling pathway is a fundamental mechanism to limit the phosphate reabsorption in the proximal renal tubule by inhibiting the phosphate co-transporters [156]. Here, FGFR1 is linked to hyperphosphatemia.